NCT06732648View on ClinicalTrials.gov

The Efficacy and Safety of HRS8179 in Severe Cerebral Edema Following Large Hemispheric Infarction

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

725

Participants

Timeline

Start Date

February 7, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

September 30, 2027

Conditions
Severe Cerebral Edema Following Large Hemispheric Infarction
Interventions
DRUG

HRS8179 injection

HRS8179 injection; high dose

DRUG

HRS8179 blank preparation.

HRS8179 blank preparation.

Trial Locations (1)

100000

RECRUITING

Beijing Tiantan Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Suncadia Pharmaceuticals Co., Ltd

INDUSTRY